I assume that it's based on the funding being drawn down in December (14.1% growth to that stage) but the 34.4% is for the full YTD?
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game